LncRNA HIF1A-AS2 modulated by HPV16 E6 regulates apoptosis of cervical cancer cells via P53/caspase9/caspase3 axis.

BACKGROUND: Plentiful evidence proves that lncRNAs play a crucial role in tumor development. However, the function and mechanism that were mediated by lncRNA HIF1A-AS2 in cervical cancer remain unclear. METHODS: The lncRNA HIF1A-AS2 was identified via high-throughput microarray analysis of three HPV 16-positive cervical squamous cell carcinoma (CSCC) samples and three HPV-negative normal controls. The expression of HIF1A-AS2 was detected by qRT-PCR in clinical tissues and cancer cells. In vitro and in vivo assays were performed through downregulation or upregulation of HIF1A-AS2. The possible mechanisms of HIF1A-AS2 in cervical cancer cells were explored by western blot, flow cytometric analysis and rescue assays. RESULTS: HIF1A-AS2 was significantly increased in cervical cancer tissue, and in the HPV- positive cervical cancer cells. Further investigation showed that the inhibition of HIF1A-AS2 suppressed cell proliferation, migration, invasion, and induced apoptosis, while up-regulation of HIF1A-AS2 revealed opposite results. In terms of mechanism, we found that HIF1A-AS2 was mediated by HPV16 E6 and regulated cell apoptosis via P53/caspase 9/caspase 3 axis. CONCLUSION: Our findings demonstrate that HIF1A-AS2 functions as a carcinogenic lncRNA that promotes tumor development, and serves as a candidate prognostic factor, which may contribute to the treatment of cervical cancer.

Long noncoding RNA SNHG12 modulated by human papillomavirus 16 E6/E7 promotes cervical cancer progression via ERK/Slug pathway.

Recently, long noncoding RNA SNHG12 has been reported to be dysregulated in various types of cancer. This study investigated its biological function and the underlying molecular mechanism in cervical squamous cell carcinoma (CSCC). We found that SNHG12 was significantly overexpressed in CSCC tissues. Further evidence showed that human papillomavirus (HPV) type 16 E6 and E7 might regulate the expression level of SNHG12 by modulating transcription factor c-Myc. Functional experiments suggested that SNHG12 knockdown dramatically repressed CSCC cells proliferation, migration, and invasion while induced apoptosis in vitro as well as suppressed tumor growth in vivo. In addition, SNHG12 could facilitate epithelial-mesenchymal transition through ERK/Slug/E-cadherin pathway at least in part. Our findings highlight SNHG12 functions as an oncogenic long noncoding RNA in malignant phenotype and tumorigenesis of CSCC, which implicate it may be a potential target for CSCC treatment.

[Effect of CIK Cells Comined with VAD on Short Prognosis of Patients with Multiple Myeloma].

OBJECTIVE: To explore the effect of CIK cells comined with VAD regimen on prognosis of patients with multiple myeloma(MM). METHODS: Forty-six cases of MM were divided into observation group and control group, the control group was treated by VAD and the observation group was treated by CIK cells comined with VAD. The prognosis between 2 groups was compared. RESULTS: The total efficiency was not significantly different between the 2 groups (P>0.05); the CR in the observation group was significantly higher than that in control group(P<0.05); the levels of osteocytes in observation group were higher than those in control group(P<0.05); the levels of osteoclasts, plasma cells, IgA and IgG in observation group were lower than those in control group(P<0.05); the increasing ranges of albumin and hemoglobin, and the decreasing range of blood sedimentation and ß2-MG in observation group were higher than those in control group(P<0.05); the incidences of abnormal electrocardiogram, myocardial enzyme and creatinine in observation group were higher than those in control group(P<0.05). CONCLUSION: CIK cells comined with VAD regimen can enhance the therapeutic effects on the patients with multiple myeloma, improve the objective index and reduce the risk of adverse reactions, thus may be applicable to clinical practice.

[Clinical Effects of Different Chemotherapeutic Regimens on the Patients with Multiple Myeloma].

OBJECTIVE: To explore the clinical effects of T-VD regimen (bortezomib+dexamethasone+thalidomid) and T-VAD regimen (vincristine+adriamycin+dexamethasone+thalidomide) on the patients with multiple myeloma(MM). METHODS: Thirty cases of MM treated by T-VD(T-VD group) and 30 cases of MM treated by T-VAD(T-VAD group) from April 2010 to April 2012 were included in this study. The clinical effects and long-term survival were compared betwwen these 2 groups. RESULTS: Both the CR and ORR in T-VD group were higher than those in T-VAD group(P<0.05); the ORR of the non-light and light chain type in T-VD group was higher than that in the T-VAD group(P<0.05); the ORR was not different between the no-light chain type and light chain type in T-VD group(P>0.05); the ORR was not different between the non-light and light chain type of T-VAD group(P>0.05); the ORR was not different between the stage I-II of T-VD group and T-VAD group(P>0.05); the ORR for the stages of III T-VD group was higher than that of T-VAD group(P<0.05); the ORR was not different between the I-II and III stages in the T-VD group(P>0.05); The ORR for the I-II stages of control group were higher than that of the III stages(P<0.05); the levels of serum M protein, myeloma cells, ß2-MG in the T-VD group were lower than those in T-VAD group(P<0.05). The rate of leukocyteopenia, nausea and vomit, weakness in T-VD group were significantly higher than those in T-VAD group(P<0.05); The incidences of infection and peripheral neuropathy in T-VD group were higher than those in T-VAD group(P<0.05). CONCLUSION: The effect of T-VD regimen on the patients with MM is better than that of T-VAD regimen and its effect is not influenced by the clinical classification and stages, but will aggravate some side effects, thus this chemotherapeutic regimen need to be carefully chosen.

[Partial splenic embolization for idiopathic thrombocytopenic purpura: therapeutic effect and influence of the embolization on splenic function].

OBJECTIVE: To explore the therapeutic effect of partial splenic embolization of different embolized volumes for idiopathic thrombocytopenic purpura (ITP) and consequent changes of the splenic function. METHODS: Forty-five ITP patients were randomized into 2 groups to receive splenic embolization with gelatin sponge particles, and the embolized volume ranged between 60% and 80% in the former group (group A), and between 40% and 60% in the latter group (group B). RESULTS: The platelet counts of the patients in both groups markedly increased one week after the operation, and the average count was significant higher in group A than in group B one year after the operation (P<0.01). The splenic function of the patients in neither of groups underwent any significant changes after the operation (P>0.05). CONCLUSION: Splenic embolization of different volumes produces similar therapeutic effect on ITP, but more extensive embolization may insure long-lasting effect with better safety and less influence on splenic function.